© 2022 MJH Life Sciences and Drug Topics. All rights reserved.
© 2022 MJH Life Sciences™ and Drug Topics. All rights reserved.
14820 PHYSICIANS LN STE 242
Lisa M. Holle, PharmD, BCOP, FHOPA is an assistant clinical professor, University of Connecticut School of Pharmacy, Storrs, Conn.
June 11, 2018
New developments in cancer treatment require medication experts-here's how you can become that expert.
February 08, 2017
Here: an overview of atezolizumab, the first new drug in two decades for bladder cancer and now approved for NSCLC.
December 19, 2016
New drug review
November 11, 2016
FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
June 10, 2016
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.